Viking Therapeutics Inc Stock
€59.52
Your prediction
Viking Therapeutics Inc Stock
Pros and Cons of Viking Therapeutics Inc in the next few years
Pros
Cons
Performance of Viking Therapeutics Inc vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Viking Therapeutics Inc | -2.500% | -7.807% | -1.064% | 206.409% | 240.406% | 1153.580% | - |
Ardelyx Inc. | -2.180% | -8.082% | -17.622% | 36.376% | 5.467% | -17.061% | - |
Salarius Pharmaceuticals Inc. | 1.850% | 7.843% | -16.981% | -69.863% | -20.721% | -98.138% | -99.994% |
Evolus Inc | -1.830% | -4.386% | -15.504% | 39.744% | 16.578% | 23.164% | - |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon initial examination of Viking's financial statements, the company's financial situation seems challenging, which is a common scenario in the biotechnology and medical research industry. Companies in this field often face significant losses and capital expenditures before reaching profitability. The next step is to provide a detailed analysis of the company's financials to understand the pros and cons better.
1. Strong Cash Position: Viking's cash position has improved over the years, despite a slight decline observed in the recent quarter. At the end of 2020, the company held $29,117,000 in cash, which grew to $36,632,000 at the end of 2022. This implies that the company has enough liquidity to support its ongoing operations and invest in future opportunities.
2. Substantial Investments: Cash flow statements reveal that between 2020 and 2022, Viking consistently invested in its business, totaling over $120 million in short-term investments. These investments can create long-term value for the company and are a positive sign for its shareholders.
News
3 Magnificent Stocks That Could Double or More by 2030
Does a 100% return in less than seven years sound pretty good? Most investors would probably say so. But which stocks are good candidates to achieve such a gain?
Three Motley Fool contributors think
Better Buy: CRISPR Therapeutics Vs. Viking Therapeutics
CRISPR Therapeutics (NASDAQ: CRSP) and Viking Therapeutics (NASDAQ: VKTX) are among the hottest mid-cap biotechs on the market. Both have delivered incredible progress in recent months, be it on the
Viking Therapeutics Is Great. Here's Why You Shouldn't Buy It.
Viking Therapeutics (NASDAQ: VKTX) has shown its strengths from a potential product perspective and an investment perspective in recent times. The company reported excellent data from clinical